CX157

DB05205InvestigationalSmall molecule

CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.

Mechanism: This drug increases the levels of three vital neurotransmitters that affect mood and anxiety: serotonin, norepinephrine and dopamine.
Curator reviewed
Primary indication: Anxiety Disorders I, Depression ICurator reviewed
Code names: CX157

Resolves to

Compound

UNIIO6L62LZJ0Q

Targets

P21397MAOA

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

Which drugs share a target with CX157, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account